[Kaposi's angiosarcoma associated with bronchopulmonary carcinoma].
Explore the source record for details and available documents.
Bronchial Neoplasms↗
Biomedical subjects
L Cirera
Publications and source records attributed to L Cirera.
VP16-213 and cyclophosphamide in advanced breast cancer. A phase II study.
Twenty-seven patients with histologically proved advanced breast cancer were given VP 16-213 and cyclophosphamide. Twenty-one had shown resistance to other chemotherapy schedules and six had experienced relapse during adjuvant chemotherapy. There were four complete responses (15%) and seven partial responses (26%). Median survival was 61 weeks and median duration of response was 31.4 weeks. All patients experienced gastrointestinal toxicity and 22 patients (81%) showed bone marrow toxicity. This regimen is effective in advanced breast cancer resistant to other chemotherapy regimens.
Adult↗
[Gaceta Sanitaria].
Explore the source record for details and available documents.
Periodicals as Topic↗
Alternating chemotherapy in advanced non-small cell lung cancer: a phase II study.
Fifty-three patients with advanced non-small cell lung cancer (NSCLC) were treated with alternating two-drug schedules cisplatin/vindesine and ifosfamide/mitomycin. Objective response (complete and partial response) was obtained in 31% (confidence limits 18.6-44%) of patients. The median duration of response was 26 weeks. The median survival was 25 weeks, with 24% of patients alive at 1 year. The toxicity was acceptable. The still poor antitumor activity of the chemotherapy schedules used and the lack of non-cross-resistance are factors that could explain the low antitumor activity of alternating chemotherapy.
Adult↗